A Phase 2 interventional study of Survodutide and Placebo in Non-alcoholic Steatohepatitis (NASH), sponsored by Boehringer Ingelheim. Completed at 154 sites in 25 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-12-03.
Sponsored by Boehringer Ingelheim · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States — 60 open to participants now, 93 under way, 13 of them phase 3. Non-alcoholic Fatty Liver Disease · United States.
Among the 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States, this one is the 39th largest by enrollment of the 460 interventional ones that give a count, is one of 57 that started in 2021, is one of 192 in phase 2, and was the 379th registered.
1,617 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 322 are open to participants now.
Browse Non-alcoholic Fatty Liver Disease studies →60 of the 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States are open now. Recruiting first, the newest first:
Regeneron Pharmaceuticals · Sites in United States
Ages 18–75
Regeneron Pharmaceuticals · Sites in United States, Puerto Rico, United Kingdom
Ages 18–75
Columbia University · Sites in United States
Ages 18–65
Regeneron Pharmaceuticals · Sites in United States
Ages 18–75
GlaxoSmithKline · Sites in United States
Ages 18–70
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 219 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 124 (57%) stop at 75 or younger; 27 take children under 18; 55 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
547 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 93 · Phase 2 213 · Phase 3 36 · Phase 4 13
First in 2000; this study’s year is marked. 57 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 295 is above the median of 60 across 1,176 interventional studies indexed under Non-alcoholic Fatty Liver Disease.
Median enrollment 56 across the 460 interventional studies, 90 across the 85 observational. Of the 420 that completed or were terminated, 216 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
246 of 547 have an industry lead sponsor. The 10 most frequent:
Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
Boehringer Ingelheim has 5 studies filed under Non-alcoholic Fatty Liver Disease — fewer than ten, so there is no comparison to draw.
22 of the studies in Non-alcoholic Fatty Liver Disease with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04951219Phase 3Madrigal Pharmaceuticals, Inc.A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE) | 2027-03 |
| NCT04833140Phase 3Massachusetts General HospitalEstrogen Administration for the Treatment of NASH in Postmenopausal Women | 2027-07-09 |
| NCT00983463Vanderbilt UniversityAbundance and Distribution of Lipids and Proteins in Nonalcoholic Fatty Liver Disease (NAFLD) | 2026-11 |
| NCT05165706Stanford UniversityLongitudinal Multi-Omic Profiles to Reveal Mechanisms of Obesity-Mediated Insulin Resistance | 2026-11-30 |
| NCT05067621Yale UniversitySemaglutide Effects in Obese Youth With Prediabetes/New Onset Type 2 Diabetes and Metabolic Dysfunction-Associated Steatotic Liver Disease | 2026-12 |
Add all 22 to your calendar (.ics) → With an account.
Among the 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is open for men and women with a liver disease called nonalcoholic steatohepatitis (NASH) and liver fibrosis. The purpose of the study is to find out whether a medicine called BI 456906 helps patients with NASH and liver fibrosis. The study tests 3 different doses of BI 456906 to find the dose that helps best. Participants are put into 4 groups randomly, which means by chance. There are 3 groups that each receive a different dose of BI 456906 and there is 1 group that receives placebo. BI 456906 and placebo are given as an injection under the skin once per week. The placebo injection looks like the BI 456906 injection but does not contain any medicine.
Participants are in the study for a little over 1 year (60 weeks). During this time, they visit the study site several times and have some video calls in addition. At the visits, the study doctors take different measurements. To see whether the treatment works, the doctors take a very small sample of liver tissue (biopsy) from each participant at the start and at the end of the study. They also examine the liver by ultrasound and MRI. The doctors also regularly check the general health of the participants.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Further inclusion criteria apply.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Survodutide
Drug: Survodutide
Drug: Survodutide
Drug: Placebo
Survodutide
Also known as: BI 456906
Placebo
Improvement (Yes/ no) From Baseline in Liver Histological Findings Based on Liver Biopsy After 48 Weeks of Treatment in Patients With NASH (NAS ≥ 4, Fibrosis F1-F3) - Actual Maintenance Treatment
Percentage of patients who had an improvement from baseline in liver histological findings based on liver biopsy after 48 weeks of treatment is reported. Percentages were rounded to one decimal place. Improvement in histological findings was defined as a composite of improvement in NASH and no worsening of fibrosis. Improvement in non-alcoholic steatohepatitis (NASH) was defined as decrease of at least 2 points in non-alcoholic fatty liver disease (NAFLD) activity score (NAS) with at least 1 point decrease in NAS subscore of either lobular inflammation or ballooning. The NAS represents the sum of subscores for steatosis (scored from 0-3), lobular inflammation (scored from 0-3) and ballooning (scored from 0-2), and the total score ranges from 0 to 8 with higher scores representing worsening of the disease. The total score for the fibrosis stage ranges from 0 to 4 with higher score indication worsening of the disease. Patients without post-baseline data were considered non-responders.
Time frame: At baseline and at 48 weeks.
Improvement (Yes/ no) From Baseline in Liver Histological Findings Based on Liver Biopsy After 48 Weeks of Treatment in Patients With NASH (NAS ≥ 4, Fibrosis F1-F3) - Planned Maintenance Treatment
Percentage of patients who had an improvement from baseline in liver histological findings based on liver biopsy after 48 weeks of treatment is reported. Percentages were rounded to one decimal place. Improvement in histological findings was defined as a composite of improvement in non-alcoholic steatohepatitis (NASH) and no worsening of fibrosis. Improvement in NASH was defined as decrease of at least 2 points in non-alcoholic fatty liver disease (NAFLD) activity score (NAS) with at least 1 point decrease in NAS subscore of either lobular inflammation or ballooning. The NAS represents the sum of subscores for steatosis (scored from 0-3), lobular inflammation (scored from 0-3) and ballooning (scored from 0-2), and the total score ranges from 0 to 8 with higher scores representing worsening of the disease. The total score for the fibrosis stage ranges from 0 to 4 with higher score indication worsening of the disease. Patients without post-baseline data were considered non-responders.
Time frame: At baseline and after 48 weeks of treatment.
Improvement of Liver Fat Content (Yes/ no) Defined as at Least 30% Relative Reduction in Liver Fat Content After 48 Weeks of Treatment Compared to Baseline Assessed by MRI-PDFF - Actual Maintenance Treatment
Percentage of participants with improvement in liver fat content is reported. Improvement in liver fat content was defined as percentage reduction from baseline of ≥30% in liver fat content after 48 weeks of treatment compared to baseline. Percentages were rounded to one decimal place. Liver fat content was assessed by Magnetic Resonance Imaging - Proton Density Fat Fraction (MRI-PDFF). Patients without post-baseline values were imputed as non-responders.
Time frame: At baseline and after 48 weeks.
Improvement of Liver Fat Content (Yes/ no) Defined as at Least 30% Relative Reduction in Liver Fat Content After 48 Weeks of Treatment Compared to Baseline Assessed by MRI-PDFF - Planned Maintenance Treatment
Percentage of participants with improvement in liver fat content is reported. Improvement in liver fat content was defined as percentage reduction from baseline of ≥30% in liver fat content after 48 weeks of treatment compared to baseline. Liver fat content was assessed by Magnetic Resonance Imaging - Proton Density Fat Fraction (MRI-PDFF). Patients without post-baseline values were imputed as non-responders.
Time frame: At baseline and at 48 weeks.
Absolute Change of Liver Fat Content From Baseline After 48 Weeks of Treatment Assessed by MRI-PDFF - Actual Maintenance Treatment
Absolute change of liver fat content (percentage \[%\]) from baseline after 48 weeks of treatment is reported. Liver fat content was assessed by Magnetic Resonance Imaging - Proton Density Fat Fraction (MRI-PDFF). Least Squares Mean (Standard error) were calculated from mixed-effect model for repeated measures (MMRM) including fixed effects for baseline liver fat content (%) as a continuous linear covariate, and treatment, presence of diabetes of any type \[yes, no\], baseline fibrosis score \[F1, F2, F3\], visit, treatment by visit interaction and baseline by visit interaction as factors.
Time frame: MMRM included measurements from baseline and at Week 28 and at Week 48 after first drug administration. MMRM estimates of absolute change from baseline to Week 48 is reported.
Absolute Change of Liver Fat Content From Baseline After 48 Weeks of Treatment Assessed by MRI-PDFF - Planned Maintenance Treatment
Absolute change of liver fat content from baseline after 48 weeks of treatment is reported. Liver fat content was assessed by Magnetic Resonance Imaging - Proton Density Fat Fraction (MRI-PDFF). Least Squares Mean (Standard error) were calculated from mixed-effect model for repeated measures (MMRM) including fixed effects for baseline liver fat content (%) as a continuous linear covariate, and treatment, presence of diabetes of any type \[yes, no\], baseline fibrosis score \[F1, F2, F3\], visit, treatment by visit interaction and baseline by visit interaction as factors.
Time frame: MMRM included measurements from baseline and at Week 28 and at Week 48 after first drug administration. MMRM estimates of absolute change from baseline to Week 48 is reported.
Percent Change of Liver Fat Content From Baseline After 48 Weeks of Treatment Assessed by MRI-PDFF - Actual Maintenance Treatment
Percent change of liver fat content (percentage \[%\]) from baseline after 48 weeks of treatment is reported. Liver fat content was assessed by Magnetic Resonance Imaging - Proton Density Fat Fraction (MRI-PDFF). Least Squares Mean (Standard error) were calculated from mixed-effect model for repeated measures (MMRM) including fixed effects for baseline liver fat content (%) as a continuous linear covariate, and treatment, presence of diabetes of any type \[yes, no\], baseline fibrosis score \[F1, F2, F3\], visit, treatment by visit interaction and baseline by visit interaction as factors.
Time frame: MMRM included measurements from baseline and at Week 28 and at Week 48 after first drug administration. MMRM estimates of percent change from baseline to Week 48 is reported.
Percent Change of Liver Fat Content From Baseline After 48 Weeks of Treatment Assessed by MRI-PDFF - Planned Maintenance Treatment
Percent change of liver fat content (percentage \[%\]) from baseline after 48 weeks of treatment is reported. Liver fat content was assessed by Magnetic Resonance Imaging - Proton Density Fat Fraction (MRI-PDFF). Least Squares Mean (Standard error) were calculated from mixed-effect model for repeated measures (MMRM) including fixed effects for baseline liver fat content (%) as a continuous linear covariate, and treatment, presence of diabetes of any type \[yes, no\], baseline fibrosis score \[F1, F2, F3\], visit, treatment by visit interaction and baseline by visit interaction as factors.
Time frame: MMRM included measurements from baseline and at Week 28 and at Week 48 after first drug administration. MMRM estimates of percent change from baseline to Week 48 is reported.
Improvement of Fibrosis (Yes/ no) Defined as at Least One Stage Decrease in Fibrosis Stage After 48 Weeks of Treatment Assessed by Liver Biopsy - Actual Maintenance Treatment
Percentage of participants with improvement of liver fibrosis is reported. Improvement of fibrosis was defined as at least one stage decrease in fibrosis stage after 48 weeks of treatment assessed by liver biopsy. The total score for the fibrosis stage ranges from 0 to 4 with higher score indication worsening of the disease and the stages of fibrosis based on their location are the following: * 1A Zone 3, perisinusoidal, delicate; * 1B Zone 3, perisinusoidal, dense; * 1C Portal, periportal only; * 2 Zone 3, perisinusoidal + portal, periportal only; * 3 Bridging fibrosis; * 4 Cirrhosis. For analysis purposes no distinction was made between stages 1A, 1B and 1C.
Time frame: At baseline and after 48 weeks of treatment.
Improvement of Fibrosis (Yes/ no) Defined as at Least One Stage Decrease in Fibrosis Stage After 48 Weeks of Treatment Assessed by Liver Biopsy - Planned Maintenance Treatment
Percentage of participants with improvement of liver fibrosis is reported. Improvement of fibrosis was defined as at least one stage decrease in fibrosis stage after 48 weeks of treatment assessed by liver biopsy. The total score for the fibrosis stage ranges from 0 to 4 with higher score indication worsening of the disease and the stages of fibrosis based on their location are the following: * 1A Zone 3, perisinusoidal, delicate; * 1B Zone 3, perisinusoidal, dense; * 1C Portal, periportal only; * 2 Zone 3, perisinusoidal + portal, periportal only; * 3 Bridging fibrosis; * 4 Cirrhosis. For analysis purposes no distinction was made between stages 1A, 1B and 1C.
Time frame: At baseline and after 48 weeks of treatment.
Absolute Change From Baseline in NAS After 48 Weeks of Treatment Assessed by Liver Biopsy - Actual Maintenance Treatment
Absolute change from baseline in NAS after 48 weeks of treatment assessed by liver biopsy is reported. The non-alcoholic fatty liver disease (NAFLD) activity score (NAS) represents the sum of subscores for steatosis (scored from 0-3), lobular inflammation (scored from 0-3) and ballooning (scored from 0-2), and the total score ranges from 0 to 8 with higher scores representing worsening of the disease.
Time frame: At baseline and 48 weeks of treatment.
Absolute Change From Baseline in NAS After 48 Weeks of Treatment Assessed by Liver Biopsy - Planned Maintenance Treatment
Absolute change from baseline in NAS after 48 weeks of treatment assessed by liver biopsy is reported. The non-alcoholic fatty liver disease (NAFLD) activity score (NAS) represents the sum of subscores for steatosis (scored from 0-3), lobular inflammation (scored from 0-3) and ballooning (scored from 0-2), and the total score ranges from 0 to 8 with higher scores representing worsening of the disease.
Time frame: At baseline and 48 weeks of treatment.
This was a 48 weeks, multi-centre, randomised, dose-ranging, double-blind, placebo-controlled, parallel-group trial to evaluate efficacy, safety and tolerability of multiple subcutaneous (s.c.) doses of survodutide (BI 456906) in patients with non-alcoholic steatohepatitis (NASH). Main parameters for inclusion of patients and for evaluation of treatment response were based on the histological evaluation from the liver biopsy and non-invasive imaging modalities.
| Milestone | Survodutide 2.4 mg - Planned Maintenance Treatment | Survodutide 4.8 mg - Planned Maintenance Treatment | Survodutide 6.0 mg - Planned Maintenance Treatment | Placebo - Planned Maintenance Treatment |
|---|---|---|---|---|
| Started | 73 | 73 | 75 | 74 |
| Treated with trial medication | 73 | 72 | 74 | 74 |
| Completed | 62 | 63 | 57 | 68 |
| Not completed | 11 | 10 | 18 | 6 |
| Withdrew: Not treated with trial medication | 0 | 1 | 1 | 0 |
| Withdrew: Other reasons than listed | 2 | 0 | 2 | 1 |
| Withdrew: Protocol violation | 0 | 0 | 3 | 1 |
| Withdrew: Burden of study procedures | 1 | 0 | 0 | 0 |
| Withdrew: Change of residence | 0 | 0 | 0 | 1 |
| Withdrew: Perceived lack of efficacy | 0 | 0 | 0 | 1 |
| Withdrew: Adverse event | 8 | 9 | 12 | 2 |
| Milestone | Survodutide 2.4 mg - Planned Maintenance Treatment | Survodutide 4.8 mg - Planned Maintenance Treatment | Survodutide 6.0 mg - Planned Maintenance Treatment | Placebo - Planned Maintenance Treatment |
|---|---|---|---|---|
| Started | 62 | 63 | 57 | 68 |
| Completed | 53 | 55 | 49 | 64 |
| Not completed | 9 | 8 | 8 | 4 |
| Withdrew: Other than listed | 4 | 2 | 0 | 3 |
| Withdrew: Burden of study procedures | 1 | 0 | 0 | 0 |
| Withdrew: Change of residence | 0 | 1 | 3 | 0 |
| Withdrew: Perceived lack of efficacy | 0 | 0 | 0 | 1 |
| Withdrew: Adverse event | 4 | 5 | 5 | 0 |
Percentage of patients who had an improvement from baseline in liver histological findings based on liver biopsy after 48 weeks of treatment is reported. Percentages were rounded to one decimal place. Improvement in histological findings was defined as a composite of improvement in NASH and no worsening of fibrosis. Improvement in non-alcoholic steatohepatitis (NASH) was defined as decrease of at least 2 points in non-alcoholic fatty liver disease (NAFLD) activity score (NAS) with at least 1 point decrease in NAS subscore of either lobular inflammation or ballooning. The NAS represents the sum of subscores for steatosis (scored from 0-3), lobular inflammation (scored from 0-3) and ballooning (scored from 0-2), and the total score ranges from 0 to 8 with higher scores representing worsening of the disease. The total score for the fibrosis stage ranges from 0 to 4 with higher score indication worsening of the disease. Patients without post-baseline data were considered non-responders.
| Percentage of participants | Survodutide 2.4 mg - Actual Maintenance Treatment | Survodutide 4.8 mg - Actual Maintenance Treatment | Survodutide 6.0 mg - Actual Maintenance Treatment | Placebo - Actual Maintenance Treatment |
|---|---|---|---|---|
| Improvement (Yes/ no) From Baseline in Liver Histological Findings Based on Liver Biopsy After 48 Weeks of Treatment in Patients With NASH (NAS ≥ 4, Fibrosis F1-F3) - Actual Maintenance Treatment | 38.7 | 63.8 | 55.8 | 15.2 |
Percentage of patients who had an improvement from baseline in liver histological findings based on liver biopsy after 48 weeks of treatment is reported. Percentages were rounded to one decimal place. Improvement in histological findings was defined as a composite of improvement in non-alcoholic steatohepatitis (NASH) and no worsening of fibrosis. Improvement in NASH was defined as decrease of at least 2 points in non-alcoholic fatty liver disease (NAFLD) activity score (NAS) with at least 1 point decrease in NAS subscore of either lobular inflammation or ballooning. The NAS represents the sum of subscores for steatosis (scored from 0-3), lobular inflammation (scored from 0-3) and ballooning (scored from 0-2), and the total score ranges from 0 to 8 with higher scores representing worsening of the disease. The total score for the fibrosis stage ranges from 0 to 4 with higher score indication worsening of the disease. Patients without post-baseline data were considered non-responders.
| percentage of participants | Survodutide 2.4 mg - Planned Maintenance Treatment | Survodutide 4.8 mg - Planned Maintenance Treatment | Survodutide 6.0 mg - Planned Maintenance Treatment | Placebo - Planned Maintenance Treatment |
|---|---|---|---|---|
| Improvement (Yes/ no) From Baseline in Liver Histological Findings Based on Liver Biopsy After 48 Weeks of Treatment in Patients With NASH (NAS ≥ 4, Fibrosis F1-F3) - Planned Maintenance Treatment | 46.6 | 62.5 | 43.2 | 13.5 |
Percentage of participants with improvement in liver fat content is reported. Improvement in liver fat content was defined as percentage reduction from baseline of ≥30% in liver fat content after 48 weeks of treatment compared to baseline. Percentages were rounded to one decimal place. Liver fat content was assessed by Magnetic Resonance Imaging - Proton Density Fat Fraction (MRI-PDFF). Patients without post-baseline values were imputed as non-responders.
| Percentage of participants | Survodutide 2.4 mg - Actual Maintenance Treatment | Survodutide 4.8 mg - Actual Maintenance Treatment | Survodutide 6.0 mg - Actual Maintenance Treatment | Placebo - Actual Maintenance Treatment |
|---|---|---|---|---|
| Improvement of Liver Fat Content (Yes/ no) Defined as at Least 30% Relative Reduction in Liver Fat Content After 48 Weeks of Treatment Compared to Baseline Assessed by MRI-PDFF - Actual Maintenance Treatment | 50.5 | 66.7 | 76.9 | 16.5 |
Percentage of participants with improvement in liver fat content is reported. Improvement in liver fat content was defined as percentage reduction from baseline of ≥30% in liver fat content after 48 weeks of treatment compared to baseline. Liver fat content was assessed by Magnetic Resonance Imaging - Proton Density Fat Fraction (MRI-PDFF). Patients without post-baseline values were imputed as non-responders.
| Percentage of participants | Survodutide 2.4 mg - Planned Maintenance Treatment | Survodutide 4.8 mg - Planned Maintenance Treatment | Survodutide 6.0 mg - Planned Maintenance Treatment | Placebo - Planned Maintenance Treatment |
|---|---|---|---|---|
| Improvement of Liver Fat Content (Yes/ no) Defined as at Least 30% Relative Reduction in Liver Fat Content After 48 Weeks of Treatment Compared to Baseline Assessed by MRI-PDFF - Planned Maintenance Treatment | 63.0 | 66.7 | 56.8 | 13.5 |
Absolute change of liver fat content (percentage \[%\]) from baseline after 48 weeks of treatment is reported. Liver fat content was assessed by Magnetic Resonance Imaging - Proton Density Fat Fraction (MRI-PDFF). Least Squares Mean (Standard error) were calculated from mixed-effect model for repeated measures (MMRM) including fixed effects for baseline liver fat content (%) as a continuous linear covariate, and treatment, presence of diabetes of any type \[yes, no\], baseline fibrosis score \[F1, F2, F3\], visit, treatment by visit interaction and baseline by visit interaction as factors.
| percentage of liver fat content | Survodutide 2.4 mg - Actual Maintenance Treatment | Survodutide 4.8 mg - Actual Maintenance Treatment | Survodutide 6.0 mg - Actual Maintenance Treatment | Placebo - Actual Maintenance Treatment |
|---|---|---|---|---|
| Absolute Change of Liver Fat Content From Baseline After 48 Weeks of Treatment Assessed by MRI-PDFF - Actual Maintenance Treatment | -10.48 (-11.92 to -9.04) | -12.80 (-14.32 to -11.28) | -12.96 (-14.62 to -11.30) | -1.89 (-3.26 to -0.51) |
Absolute change of liver fat content from baseline after 48 weeks of treatment is reported. Liver fat content was assessed by Magnetic Resonance Imaging - Proton Density Fat Fraction (MRI-PDFF). Least Squares Mean (Standard error) were calculated from mixed-effect model for repeated measures (MMRM) including fixed effects for baseline liver fat content (%) as a continuous linear covariate, and treatment, presence of diabetes of any type \[yes, no\], baseline fibrosis score \[F1, F2, F3\], visit, treatment by visit interaction and baseline by visit interaction as factors.
| percentage of liver fat content | Survodutide 2.4 mg - Planned Maintenance Treatment | Survodutide 4.8 mg - Planned Maintenance Treatment | Survodutide 6.0 mg - Planned Maintenance Treatment | Placebo - Planned Maintenance Treatment |
|---|---|---|---|---|
| Absolute Change of Liver Fat Content From Baseline After 48 Weeks of Treatment Assessed by MRI-PDFF - Planned Maintenance Treatment | -10.73 (-12.25 to -9.22) | -12.40 (-13.90 to -10.91) | -12.48 (-14.06 to -10.89) | -1.61 (-3.04 to -0.19) |
Percent change of liver fat content (percentage \[%\]) from baseline after 48 weeks of treatment is reported. Liver fat content was assessed by Magnetic Resonance Imaging - Proton Density Fat Fraction (MRI-PDFF). Least Squares Mean (Standard error) were calculated from mixed-effect model for repeated measures (MMRM) including fixed effects for baseline liver fat content (%) as a continuous linear covariate, and treatment, presence of diabetes of any type \[yes, no\], baseline fibrosis score \[F1, F2, F3\], visit, treatment by visit interaction and baseline by visit interaction as factors.
| percent change of liver fat content | Survodutide 2.4 mg - Actual Maintenance Treatment | Survodutide 4.8 mg - Actual Maintenance Treatment | Survodutide 6.0 mg - Actual Maintenance Treatment | Placebo - Actual Maintenance Treatment |
|---|---|---|---|---|
| Percent Change of Liver Fat Content From Baseline After 48 Weeks of Treatment Assessed by MRI-PDFF - Actual Maintenance Treatment | -50.92 (-58.05 to -43.80) | -62.79 (-70.26 to -55.32) | -64.30 (-72.48 to -56.12) | -7.28 (-14.06 to -0.50) |
Percent change of liver fat content (percentage \[%\]) from baseline after 48 weeks of treatment is reported. Liver fat content was assessed by Magnetic Resonance Imaging - Proton Density Fat Fraction (MRI-PDFF). Least Squares Mean (Standard error) were calculated from mixed-effect model for repeated measures (MMRM) including fixed effects for baseline liver fat content (%) as a continuous linear covariate, and treatment, presence of diabetes of any type \[yes, no\], baseline fibrosis score \[F1, F2, F3\], visit, treatment by visit interaction and baseline by visit interaction as factors.
| percent change of liver fat content | Survodutide 2.4 mg - Planned Maintenance Treatment | Survodutide 4.8 mg - Planned Maintenance Treatment | Survodutide 6.0 mg - Planned Maintenance Treatment | Placebo - Planned Maintenance Treatment |
|---|---|---|---|---|
| Percent Change of Liver Fat Content From Baseline After 48 Weeks of Treatment Assessed by MRI-PDFF - Planned Maintenance Treatment | -52.20 (-59.66 to -44.75) | -60.82 (-68.16 to -53.48) | -61.97 (-69.78 to -54.16) | -5.71 (-12.70 to 1.28) |
Percentage of participants with improvement of liver fibrosis is reported. Improvement of fibrosis was defined as at least one stage decrease in fibrosis stage after 48 weeks of treatment assessed by liver biopsy. The total score for the fibrosis stage ranges from 0 to 4 with higher score indication worsening of the disease and the stages of fibrosis based on their location are the following: * 1A Zone 3, perisinusoidal, delicate; * 1B Zone 3, perisinusoidal, dense; * 1C Portal, periportal only; * 2 Zone 3, perisinusoidal + portal, periportal only; * 3 Bridging fibrosis; * 4 Cirrhosis. For analysis purposes no distinction was made between stages 1A, 1B and 1C.
| Percentage of participants | Survodutide 2.4 mg - Actual Maintenance Treatment | Survodutide 4.8 mg - Actual Maintenance Treatment | Survodutide 6.0 mg - Actual Maintenance Treatment | Placebo - Actual Maintenance Treatment |
|---|---|---|---|---|
| Improvement of Fibrosis (Yes/ no) Defined as at Least One Stage Decrease in Fibrosis Stage After 48 Weeks of Treatment Assessed by Liver Biopsy - Actual Maintenance Treatment | 30.1 | 34.8 | 44.2 | 21.5 |
Percentage of participants with improvement of liver fibrosis is reported. Improvement of fibrosis was defined as at least one stage decrease in fibrosis stage after 48 weeks of treatment assessed by liver biopsy. The total score for the fibrosis stage ranges from 0 to 4 with higher score indication worsening of the disease and the stages of fibrosis based on their location are the following: * 1A Zone 3, perisinusoidal, delicate; * 1B Zone 3, perisinusoidal, dense; * 1C Portal, periportal only; * 2 Zone 3, perisinusoidal + portal, periportal only; * 3 Bridging fibrosis; * 4 Cirrhosis. For analysis purposes no distinction was made between stages 1A, 1B and 1C.
| Percentage of participants | Survodutide 2.4 mg - Planned Maintenance Treatment | Survodutide 4.8 mg - Planned Maintenance Treatment | Survodutide 6.0 mg - Planned Maintenance Treatment | Placebo - Planned Maintenance Treatment |
|---|---|---|---|---|
| Improvement of Fibrosis (Yes/ no) Defined as at Least One Stage Decrease in Fibrosis Stage After 48 Weeks of Treatment Assessed by Liver Biopsy - Planned Maintenance Treatment | 34.2 | 36.1 | 33.8 | 21.6 |
Absolute change from baseline in NAS after 48 weeks of treatment assessed by liver biopsy is reported. The non-alcoholic fatty liver disease (NAFLD) activity score (NAS) represents the sum of subscores for steatosis (scored from 0-3), lobular inflammation (scored from 0-3) and ballooning (scored from 0-2), and the total score ranges from 0 to 8 with higher scores representing worsening of the disease.
| units on a scale | Survodutide 2.4 mg - Actual Maintenance Treatment | Survodutide 4.8 mg - Actual Maintenance Treatment | Survodutide 6.0 mg - Actual Maintenance Treatment | Placebo - Actual Maintenance Treatment |
|---|---|---|---|---|
| Absolute Change From Baseline in NAS After 48 Weeks of Treatment Assessed by Liver Biopsy - Actual Maintenance Treatment | -2.8 ± 1.8 | -3.2 ± 1.8 | -3.3 ± 2.0 | -0.4 ± 1.6 |
Absolute change from baseline in NAS after 48 weeks of treatment assessed by liver biopsy is reported. The non-alcoholic fatty liver disease (NAFLD) activity score (NAS) represents the sum of subscores for steatosis (scored from 0-3), lobular inflammation (scored from 0-3) and ballooning (scored from 0-2), and the total score ranges from 0 to 8 with higher scores representing worsening of the disease.
| units on a scale | Survodutide 2.4 mg - Planned Maintenance Treatment | Survodutide 4.8 mg - Planned Maintenance Treatment | Survodutide 6.0 mg - Planned Maintenance Treatment | Placebo - Planned Maintenance Treatment |
|---|---|---|---|---|
| Absolute Change From Baseline in NAS After 48 Weeks of Treatment Assessed by Liver Biopsy - Planned Maintenance Treatment | -2.8 ± 1.8 | -3.2 ± 1.8 | -3.3 ± 1.9 | -0.2 ± 1.5 |
Collected over [All-Cause Mortality], [Serious Adverse Events], [Other Adverse Events]: From first study drug administration until last study drug administration plus 28 days of residual effect period (REP), up to 365 days.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Survodutide 2.4 mg - Actual Maintenance Treatment | 0/93 (0%) | 5/93 (5.4%) | 85/93 (91.4%) |
| Survodutide 4.8 mg - Actual Maintenance Treatment | 0/69 (0%) | 7/69 (10.1%) | 60/69 (87%) |
| Survodutide 6.0 mg - Actual Maintenance Treatment | 0/52 (0%) | 5/52 (9.6%) | 49/52 (94.2%) |
| Placebo - Actual Maintenance Treatment | 0/79 (0%) | 5/79 (6.3%) | 68/79 (86.1%) |
| Event | Survodutide 2.4 mg - Actual Maintenance Treatment | Survodutide 4.8 mg - Actual Maintenance Treatment | Survodutide 6.0 mg - Actual Maintenance Treatment | Placebo - Actual Maintenance Treatment |
|---|---|---|---|---|
| CholelithiasisHepatobiliary disorders | 0/93 | 0/69 | 2/52 | 0/79 |
| Hepatic cirrhosisHepatobiliary disorders | 0/93 | 0/69 | 1/52 | 1/79 |
| Amylase increasedInvestigations | 0/93 | 0/69 | 1/52 | 0/79 |
| Blood creatinine increasedInvestigations | 0/93 | 0/69 | 1/52 | 0/79 |
| Glomerular filtration rate decreasedInvestigations | 0/93 | 0/69 | 1/52 | 0/79 |
| Lipase increasedInvestigations | 0/93 | 0/69 | 1/52 | 0/79 |
| DehydrationMetabolism and nutrition disorders | 0/93 | 0/69 | 1/52 | 0/79 |
| NephrolithiasisRenal and urinary disorders | 0/93 | 1/69 | 1/52 | 0/79 |
| Acute myocardial infarctionCardiac disorders | 0/93 | 1/69 | 0/52 | 0/79 |
| Sudden hearing lossEar and labyrinth disorders | 0/93 | 1/69 | 0/52 | 0/79 |
| Event | Survodutide 2.4 mg - Actual Maintenance Treatment | Survodutide 4.8 mg - Actual Maintenance Treatment | Survodutide 6.0 mg - Actual Maintenance Treatment | Placebo - Actual Maintenance Treatment |
|---|---|---|---|---|
| NauseaGastrointestinal disorders | 60/93 | 46/69 | 33/52 | 22/79 |
| DiarrhoeaGastrointestinal disorders | 38/93 | 37/69 | 29/52 | 20/79 |
| VomitingGastrointestinal disorders | 38/93 | 33/69 | 15/52 | 6/79 |
| ConstipationGastrointestinal disorders | 16/93 | 12/69 | 15/52 | 14/79 |
| HeadacheNervous system disorders | 21/93 | 12/69 | 6/52 | 13/79 |
| COVID-19Infections and infestations | 19/93 | 15/69 | 5/52 | 16/79 |
| Decreased appetiteMetabolism and nutrition disorders | 20/93 | 9/69 | 8/52 | 8/79 |
| DyspepsiaGastrointestinal disorders | 14/93 | 6/69 | 11/52 | 3/79 |
| FatigueGeneral disorders | 18/93 | 10/69 | 8/52 | 7/79 |
| NasopharyngitisInfections and infestations | 6/93 | 12/69 | 4/52 | 10/79 |
Treated set - planned maintenance treatment: included all patients that were administered survodutide or placebo matching survodutide. Patients are analyzed according to the planned treatment (planned maintenance dose strength) they were assigned at randomisation even if patients did not reach the maintenance period at all, and therefore did not "settle" on any maintenance dose.
| Age, Continuous(years) | Survodutide 2.4 mg - Planned Maintenance Treatment | Survodutide 4.8 mg - Planned Maintenance Treatment | Survodutide 6.0 mg - Planned Maintenance Treatment | Placebo - Planned Maintenance Treatment | Total |
|---|---|---|---|---|---|
| Mean | 49.6 ± 13.7 | 50.2 ± 12.9 | 50.4 ± 13.1 | 53.0 ± 11.5 | 50.8 ± 12.8 |
| Sex: Female, Male(Participants) | Survodutide 2.4 mg - Planned Maintenance Treatment | Survodutide 4.8 mg - Planned Maintenance Treatment | Survodutide 6.0 mg - Planned Maintenance Treatment | Placebo - Planned Maintenance Treatment | Total |
|---|---|---|---|---|---|
| Female | 36 | 34 | 41 | 44 | 155 |
| Male | 37 | 38 | 33 | 30 | 138 |
| Ethnicity (NIH/OMB)(Participants) | Survodutide 2.4 mg - Planned Maintenance Treatment | Survodutide 4.8 mg - Planned Maintenance Treatment | Survodutide 6.0 mg - Planned Maintenance Treatment | Placebo - Planned Maintenance Treatment | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 14 | 19 | 26 | 22 | 81 |
| Not Hispanic or Latino | 59 | 53 | 48 | 52 | 212 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Survodutide 2.4 mg - Planned Maintenance Treatment | Survodutide 4.8 mg - Planned Maintenance Treatment | Survodutide 6.0 mg - Planned Maintenance Treatment | Placebo - Planned Maintenance Treatment | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 1 | 0 | 1 |
| Asian | 24 | 22 | 17 | 17 | 80 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 1 | 1 |
| Black or African American | 2 | 3 | 0 | 0 | 5 |
| White | 46 | 47 | 56 | 56 | 205 |
| More than one race | 1 | 0 | 0 | 0 | 1 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| NAS score at baseline(score on a scale) | Survodutide 2.4 mg - Planned Maintenance Treatment | Survodutide 4.8 mg - Planned Maintenance Treatment | Survodutide 6.0 mg - Planned Maintenance Treatment | Placebo - Planned Maintenance Treatment | Total |
|---|---|---|---|---|---|
| Mean | 5.2 ± 1.0 | 5.3 ± 1.1 | 5.1 ± 1.0 | 5.2 ± 1.1 | 5.2 ± 1.0 |
| Number of participants at each category of liver fibrosis stage at baseline(Participants) | Survodutide 2.4 mg - Planned Maintenance Treatment | Survodutide 4.8 mg - Planned Maintenance Treatment | Survodutide 6.0 mg - Planned Maintenance Treatment | Placebo - Planned Maintenance Treatment | Total |
|---|---|---|---|---|---|
| Stage 1A | 0 | 3 | 3 | 2 | 8 |
| Stage 1B | 17 | 7 | 14 | 9 | 47 |
| Stage 1C | 3 | 3 | 6 | 3 | 15 |
| Stage 2 | 30 | 36 | 24 | 30 | 120 |
| Stage 3 | 23 | 23 | 27 | 30 | 103 |
| Number of participants in each category of diabetes at baseline(Participants) | Survodutide 2.4 mg - Planned Maintenance Treatment | Survodutide 4.8 mg - Planned Maintenance Treatment | Survodutide 6.0 mg - Planned Maintenance Treatment | Placebo - Planned Maintenance Treatment | Total |
|---|---|---|---|---|---|
| No | 44 | 43 | 44 | 45 | 176 |
| Yes | 29 | 29 | 30 | 29 | 117 |
| Number of patients in each category of NAS score(Participants) | Survodutide 2.4 mg - Planned Maintenance Treatment | Survodutide 4.8 mg - Planned Maintenance Treatment | Survodutide 6.0 mg - Planned Maintenance Treatment | Placebo - Planned Maintenance Treatment | Total |
|---|---|---|---|---|---|
| 0 | 0 | 0 | 0 | 0 | 0 |
| 1 | 0 | 0 | 0 | 0 | 0 |
| 2 | 0 | 0 | 0 | 0 | 0 |
| 3 | 0 | 0 | 0 | 0 | 0 |
| 4 | 21 | 20 | 26 | 22 | 89 |
| 5 | 27 | 21 | 17 | 28 | 93 |
| 6 | 17 | 22 | 26 | 8 | 73 |
| 7 | 8 | 8 | 5 | 16 | 37 |
| 8 | 0 | 1 | 0 | 0 | 1 |
2 further baseline measures are reported on the registry.
Showing the first 100 of 154 sites across 25 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — After the study is completed and the primary manuscript is accepted for publishing, researchers can use this following link https://www.mystudywindow.com/msw/datasharing to request access to the clinical study documents regarding this study, and upon a signed "Document Sharing Agreement". Also, Researchers can use the following link https://www.mystudywindow.com/msw/datasharing to find information in order to request access to the clinical study data, for this and other listed studies, after the submission of a research proposal and according to the terms outlined in the website. The data shared are the raw clinical study data sets.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: After all regulatory activities are completed in the US and EU for the product and indication, and after the primary manuscript has been accepted for publication.
Access criteria: For study documents - upon signing of a 'Document Sharing Agreement'. For study data - 1. after the submission and approval of the research proposal (checks will be performed by both the independent review panel and the sponsor, including checking that the planned analysis does not compete with sponsor's publication plan); 2. and upon signing of a 'Data Sharing Agreement'.
Data sharing details ↗ · www.mystudywindow.com
Ran from Apr 2021 to primary completion in Nov 2023, 30 months.
Results were first posted in Dec 2024, 1 year after primary completion.
Of 132 industry-sponsored phase 2 interventional studies under Non-alcoholic Fatty Liver Disease, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 30. This study's 30 months is above that.
Counting every sponsor, half of 185 studies reached it within 26 months; a quarter within 16 and three quarters within 36.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Survodutide
Non-alcoholic Fatty Liver Disease →